Positive POI results for Orexa’s ORE-001

9 October 2025

Orexa, a privately-held biopharma developing drugs to increase food intake, especially for post-surgery patients, has presented positive trial results on its lead drug candidate.

The Dutch company revealed interim results from its ongoing Phase II trial evaluating ORE-001 in the prevention of post-operative ileus (POI) in patients undergoing major abdominal surgery.

This trial is a multicenter, randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of ORE-001 and is enrolling 100 to 120 female patients undergoing gynecologic surgery requiring longitudinal laparotomy. It is being conducted at multiple centers in Germany with lead investigator Alexander Mustea from Universitätsklinikum Bonn.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK